Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare.
The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry.
Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.
Mark Kaufman, science reporter at Mashable, discusses President Trump's surprising pick to lead the White House Office of Science and Technology Policy, atmospheric scientist Kelvin Droegemeier.
These are the headlines you Need2Know for Thursday.
The electric automaker said most factories would hit a run rate of 10,000 of the mass-market vehicles a week by the end of the year, suggesting the company could be on the path to achieving profitability. The company did still report a wider loss than expected for the current quarter, but it said it burned through less cash than in the first quarter.
These are the headlines you Need2Know.
These are the headlines you Need2Know.
Narcan, the nasal spray that saved Demi Lovato from overdosing, is now available without a prescription in 49 states. Roger Crystal, MD, CEO of Opiant Pharmaceuticals and founder of the drug, was interviewed Thursday by Cheddar.
These are the headlines you Need2Know.
These are the headlines you Need2Know.
A recent survey by research firm Cohn & Wolfe found that 86 percent of Americans think companies should be socially and environmentally responsible. Burt's Bees is carbon-neutral certified and hasn't sent any waste to a landfill since 2010. Paula Alexander, Director of Sustainable Business at the company, tells Cheddar why it's important to work for a company that makes a difference.
Peter Loftus, Reporter at the Wall Street Journal, is skeptical of pharmaceutical companies touting lower drug prices. Merck may be cutting prices on medications, Loftus told Cheddar, but the ones affected represent a smaller percentage of the company's total sales.
